The inflammatory response must be constantly constrained to prevent molecular, cellular and organ damage. The consequences of unregulated inflammation are associated with or directly underpin many diseases that plague humans, including autoimmune and metabolic diseases, infectious diseases caused by large macroparasites, viruses, chronic neurological diseases, malignancy, and life-threatening acute responses to pathogen products such as sepsis and shock. Correspondingly, a proportionate share of the modern pharmacopoeia is devoted to blocking inflammation, from widely used drugs such as aspirin and nonsteroidal anti-inflammatory medications to humanized antibodies to inflammatory cytokines.
Given that the inflammatory response is essential for constraining infection, for the recruitment and activation of lymphocytes and then the promotion of wound healing and repair, how are these processes regulated such that 'horror autotoxicus' (autoimmunity) is mitigated and organ systems return to homeostasis? The integration of inflammatory inhibition and homeostasis is especially important in large animals that must live for decades to successfully reproduce and raise the next generation. It should not be surprising, therefore, that elaborate mechanisms to regulate inflammation have evolved together with proinflammatory pathways, that nonresolving or chronic inflammation is linked to the chronic maladies of aging and that older organisms are especially sensitive to inflammatory perturbation 1 .
Before the discovery of 'innate' detection systems such as the Toll-like receptors (TLRs), Nod-like receptors (NLRs), C-type lectin receptors and the diverse detectors of nucleic acids, 'negative' pathways had been recognized as regulating multiple layers of the inflammatory response. Subsequent to the proposal that innate receptors have preeminent roles in pathogen detection and the initiation of inflammation, a massive literature has established additional layers of regulatory control over inflammation. In this overview, we cannot cover the primary literature on the fine details of each molecule attributed to have a negative regulatory influence on inflammation. Instead, we first propose that modulation of inflammation involves interconnected layers or strata that begins with the anatomy of mammals and extends to the precise control of the metabolic state of inflammatory cells. From those regulatory strata, we will focus on three interrelated pathways whose mechanistic details are emerging and represent new strategies with which to manipulate and interrupt excessive responses initiated by TLR signaling and related pathways that activate inflammation. As other reviews have covered aspects of inflammatory modulation, including TLR signaling components and post-transcriptional pathways [2] [3] [4] [5] [6] [7] we will focus on the wider context of inflammatory regulation.
Discovery of anti-inflammatory pathways
Three types of investigation have identified negative regulators of inflammation. First, observations of unanticipated phenotypes in humans and mutant mice with inflammatory disease have been the starting point for the discovery of many key pathways, including the interleukin 10 (IL-10) and transforming growth factor-β (TGF-β) pathways [8] [9] [10] . Second, standard experimental models of inflammation (including cecal ligation and puncture; endotoxin challenge; bleomycinmediated lung injury; graft-versus-host disease; airway challenge of mice with allergens and TLR agonists; and infection models that include acute and chronic inflammation-associated damage) have led to the definition of many anti-inflammatory pathways. Third, in vitro systems for measuring the TLR-and NLR-activated pathways in primary cultures of macrophages and dendritic cells from knockout r e v i e w and transgenic mice have been instrumental in pinpointing where a given regulatory factor fits into a signaling pathway. Through experiments using those systems coupled with complementary approaches such as forward genetics and biochemical reconstitution experiments, many anti-inflammatory factors been discovered and their activities defined to differing extents (Table 1) . Nevertheless, caveats apply for such approaches that center on the model systems used and their context. First, many types of experiments in mice cannot be applied to humans. Mouse models of inflammation can amplify the preeminence of pathways that are subject to compensatory or redundant effects in people. For example, humans deficient in the adaptor MyD88 have a narrow range of infection phenotypes even in adulthood, whereas MyD88-deficient mice have broad phenotypes consistent with the key role of MyD88 in all TLR signaling pathways (other than TLR3) 11 . Such observations are best reconciled by the fact that humans are not exposed to the same experimental pressure present in a procedure such as cecal ligation and puncture 12 . Future studies of humans, mice and new model organisms such as the pig 13, 14 will probably refine the understanding of the existing anti-inflammatory pathways and identify additional regulatory layers.
A second caveat concerns the interpretation of links between molecules that have many functions and whose disruption causes excessive inflammation. Tracing the connections between pathways has proven difficult when the starting point is a whole-animal experiment. An informative example is the whole-mouse disruption of SOCS1, an inducible inhibitor of the receptors for type I and II interferons 15 . Deletion of Socs1 leads to death of mice a few weeks after birth, a phenotype that can be 'rescued' by crossing Socs1 −/− mice to mice on backgrounds deficient in interferon-γ (IFN-γ (Ifng −/− mice)) or recombination-activating gene 1. However, Socs1 −/− Ifng −/− mice (as well as juvenile Socs1 −/− mice) are extraordinarily sensitive to the systemic administration of endotoxin 16, 17 . Several models have been proposed to account for this phenotype, including absence of regulation of TLR signaling by direct binding of SOCS1 to the adaptor TIRAP (Mal), the kinase IRAK1 and the transcription factor NF-κB, and excessive signaling via IFN-α and IFN-β in the Socs1 −/− Ifng −/− mice [16] [17] [18] [19] [20] . Collectively these data show that for a protein like SOCS1, which has many effects in various cell types and contexts, probing the inflammatory strata to assign a relative hierarchy of negative regulation is complex.
Inflammation has a clock
In vivo, the inhibition of inflammatory pathways occurs on a time frame that extends from seconds to years in wound healing and tissue 119 Gene deletions that result in enhanced inflammation, categorized by the stratification of the inflammatory pathways. Many other gene deletions have been linked to negative effects on inflammatory responses; mouse loss-of-function alleles were the main criteria for inclusion here. PAMP, pathogen-associated molecular pattern.
npg r e v i e w repair or is continuously ongoing in chronic inflammation. For productive immunity to pathogens to emerge, the initial inflammatory insult needs to be sufficient to trigger a response beyond the homeostatic anti-inflammatory threshold 21 . For example, in the gut, IL-10 constitutively dampens signaling by TLR and NLR from the gut flora to maintain normal intestinal function. Infection with a pathogen such as Shigella flexneri, which invades the mucosal layers, triggers a response that exceeds the homeostatic threshold 21 and causes massive inflammation 22 . The signals to repair the gut probably begin once the infection is 'controlled' , such that bacteria may still be present but are no longer proliferating. In the gut, repair mechanisms to restore the epithelia and mucosa must work very quickly, as all animals need to acquire nutrients to survive. In contrast, the wound-healing and tissuerestoration process for bones, deep tissue injuries and muscles takes months to years to restore tissue strength. Regardless of the time frame of tissue repair, negative regulation of inflammation must be continuously engaged. Thus, productive regulatory pathways are induced proportionally to the inflammatory insult and are themselves subject to additional layers of regulation 23 . An informative example of this is the production of IL-10, which is essential for the inhibition of inflammation on many layers but can also promote an immunological environment permissive for many pathogens 24 . Obviously, lack of engagement of counter-regulation at the correct time and place underlies many of the inflammatory diseases noted here.
Cell-intrinsic and cell-extrinsic anti-inflammation strata
It is plausible to consider that for every proinflammatory pathway activated by the microbe-and cell damage-sensing systems, there are at least as many anti-inflammatory pathways. Anti-inflammatory pathways can be crudely divided into cell-intrinsic and cell-extrinsic mechanisms, many of which have been identified by unexpected outcomes of the detailed examination of genetically modified mice that manifest inflammatory diseases. Examples of cell-intrinsic pathways include co-regulated inhibitors of TLR signaling, such as IκBα, IRAK-M, A20 and ABIN1 ( Table 1) . Deletion of each of these factors in mice leads to complex inflammatory diseases due to failure to attenuate inflammatory signaling after it has been initiated by a microbial product or proinflammatory cytokine such as tumor necrosis factor (TNF) [25] [26] [27] [28] [29] . Cell-extrinsic mechanisms include anti-inflammatory cytokines such as IL-10 and TGF-β, as well as myriad factors that function to block inflammation through the sequential 'repair' process outlined above. Another way to define anti-inflammatory pathways is to break down each step from the initiation of inflammation to its resolution. These strata constitute an integrated system for mitigating the negative effects of inflammation through the span of an inflammatory response. We have summarized these strata as a 'snapshot' of the breadth of inflammatory modulation and have provided selected examples of gene disruptions in mice that lead to excessive inflammation ( Table 1) . Many papers on inflammation begin with a statement concerning the 'first-line' functions of the innate immune response. However, the first line of defense against pathogens is mammalian anatomy (stratum 1) and its associated mucosal system (stratum 2). The lungs, gut and skin receive constant stimulation by commensals and pathogens 30 . However, it is rare that inflammatory responses are sufficiently troublesome to require a visit to the doctor. Human barrier systems have evolved to mechanically repel or constrain microorganisms that could trigger inflammation. A key example is the mucosal lining of the gut, where both the viscosity and forward motion ensures that only a fraction of the gut flora encounters the underlying mucosa rich in cells of the immune system. Similarly, the lungs are bathed in surfactant to restrain colonization by microorganisms, an effect that is complemented by the cough reflex that continuously propels mucus and debris from the lungs upward. The effects of disruption of the lung mucosal lining and failure to cough are key elements of cystic fibrosis and the bacterial overgrowth observed in terminally ill patients. Similarly, defects in intestinal mucus production or flow are associated with substantial inflammatory responses 31, 32 . The gut, liver, skin, spleen and lungs are also endowed with sentinel cells of the immune system programmed not to overreact to pathogens or their products 30, 33, 34 . The spleen is also the target of the neural-reflex anti-inflammatory pathway 35 . Collectively, the anatomy of mammals contributes the bulk of defense against pathogen challenge and the initiation of inflammation.
The removal of microbial products, including cell-wall components, before they ever interact with TLRs and NLRs is a key innate mode of inflammatory regulation. Along with anatomical restriction of exposure to TLR ligands via strata 1 and 2, the sequestration of pathogen-associated molecular patterns (stratum 3) operates continuously. The complexity of the pathways in stratum 3 has been reviewed 5 . Two other 'innate' pathways that interface with anatomy, mucous membranes and circulatory system are the complement and coagulation pathways. The effect of these two pathways on pro-and anti-inflammatory modulation of TLR signaling is an emerging area of investigation, along with modulation of the extracellular matrix, and has been discussed in other reviews [36] [37] [38] .
The myriad cytoplasmic proteins that work together to downregulate cell-autonomous TLR signaling 3,39 represent stratum 4 of regulation. These proteins fall into diverse structural and functional groups, including sentinel proteins that rapidly inhibit signaling (IRAK-M, A20, ABIN1, IκBα, Tollip and DAP12), proteins that are further induced at the gene-expression level to reinforce signaling downregulation (A20, IκBα and phosphatases of the DUSP family), kinases that mediate downstream inhibitory pathways (MSK1 and MSK2) and signaling proteins that initiate the production of cytokines that act through autocrine and paracrine pathways to block signaling (TRAF3). Other proteins, such as the alanine-rich myristoylated protein MARCKS (one example of many), have been shown to inhibit TLR signaling through unknown mechanisms 40 . The integration of each of these proteins into greater signaling networks is central to the 'decision' of each TLR-responsive cell to terminate or perpetuate an inflammatory response.
After the integration of initial TLR-signaling pathways in the cytoplasm, a large cohort of positively and negatively acting transcription factors control the thousands of genes regulated by TLR signaling (stratum 5) 41 . Negative regulation of TLR-mediated transcription can be described by at least four phenomena: specific negative feedback mechanisms to suppress the activities of factors such as NF-κB that activate the transcription of genes encoding inflammatory molecules 42 ; acquired resistance to transcriptional activation after chronic exposure to stimuli such as lipopolysaccharide (LPS) and TNF 43 , usually referred to as 'endotoxin tolerance' 44 ; gene-specific effects of receptors for steroid hormones and their cofactors 45, 46 ; and the autocrine-paracrine effects of IL-10, which signals to suppress many TLR-activated genes 47 . The effects of these pathways are discussed in greater depth below. In addition to those four mechanisms, constitutively expressed transcription factors and chromatin proteins have been demonstrated to have negative effects of TLR-regulated gene expression in macrophages, although the relationship between those factors and tolerance, repression of steroid hormones, IL-10 signaling and other physiological processes related to inflammatory diseases and the resolution of normal inflammatory responses remains unclear 48 7 . Many RNA-binding proteins, such as tristetraprolin (TTP) and HuR, and microRNAs, including miR-155, are involved in fine-tuning the post-transcription inflammatory response [49] [50] [51] . Although several components of the post-transcriptional signaling network have been identified, further work is needed to pinpoint how proteins and microRNAs with broad specificity for mRNA substrates locate their targets, suppress transcription and translation and are themselves regulated.
The processing and secretion of proteins can be grouped as another layer of regulation (stratum 7). Inflammatory stress is coupled to the endoplasmic reticulum stress response. This response inhibits the processing and secretion of many proteins, presumably as a means of conserving resources during stress. However, this response is regulated by TLR signaling, such that many secreted inflammatory cytokines and chemokines are allowed to escape the endoplasmic reticulum 52, 53 . This remarkable process is required for the overall inflammatory response, but how is it regulated? Conceivably, numerous anti-inflammatory pathways could converge on the endoplasmic reticulum to suppress the production of many proinflammatory mediators that so far remain unknown.
The inhibitory pathways represented by decoy receptors, receptor antagonists and 'hijacked' cytokines (strata 8 and 9) are discussed in greater detail later. A final stratum for control of inflammation (stratum 10) is the effect of metabolic states on immunity. The metabolic control of inflammation encompasses a large variety of linked processes, including translation control, metabolic stress responses 54 , autophagy 55 and forms of programmed cell death. Emerging information on metabolism and the immune response is discussed in depth in another Review in this Focus 56 .
An example of the links between the strata of inflammatory control is the production, secretion and bioavailability of IL-1β, which is negatively regulated by at least eight different checkpoints (Fig. 1) .
Transcriptional repression of inflammation
As mentioned above, studies of the transcription of genes encoding inflammatory molecules have identified many transcription factors, chromatin proteins and other transcription-related mechanisms that contribute to the suppression of inflammation. One notable example is the rapid transcriptional activation of the gene encoding IκBα by most or all inflammatory stimuli. The induction of IκBα leads to the suppression of NF-κB activity, which attenuates the transcription of NF-κB-dependent genes unless the stimulus is able to circumvent the suppression 40 . The variable consequences of this suppression mechanism are apparent by comparison of macrophages stimulated with TNF or LPS 57, 58 . The initial response to TNF is transient because of the upregulation of IκBα, the rapid internalization of the receptor for TNF and other feedback inhibitory mechanisms. In contrast, LPS stimulates two distinct NF-κB-inducing pathways with different kinetics (the MyD88 and TRIF pathways), which allows sustained NF-κB activation and a transcriptional cascade that differs substantially from that activated by TNF, despite the upregulation of IκBα by both stimuli. Several other mechanisms that have the potential to suppress NF-κB activity have been described and are summarized elsewhere 40 . One challenge in the study of these suppression mechanisms is that their precise physiological relevance during the course of a normal inflammatory response and during abnormal responses associated with disease has been difficult to identify and therefore remains poorly understood.
In addition to the various mechanisms involved in the broad suppression of NF-κB activity, the transcription of specific sets of genes encoding inflammatory molecules is limited by several other proteins and protein complexes. Two examples are the Mi-2-NuRD complex and Bcl-6, both of which are constitutively expressed in macrophages. Mi-2-NuRD is a multiprotein complex that has histone-deacetylase and ATP-dependent nucleosome-remodeling activities and has been linked mainly to transcriptional repression 59 . Deletion of this complex in mouse macrophages leads to greatly enhanced expression of a subset of LPS-induced genes in a stimulusdependent manner 60 . The genes that are sensitive to knockdown of Mi-2-NuRD correspond to those that require remodeling of the nucleosome by another family of ATP-dependent nucleosomeremodeling complexes (the SWI-SNF family) for their transcriptional activation. Many of these remodeling-dependent genes, Figure 1 Negative regulation of IL-1β production, signaling and bioavailability as an example of multitiered anti-inflammatory integration. IL-1β is inhibited by at least eight interrelated mechanisms, including the initial counterregulation of TLR signaling, sustained TTP activity via DUSP1, transcriptional inhibition by IL-10, mRNA processing by TTP and related mRNA-binding proteins (regulated by IL-10), the type I interferon-mediated inhibition of the NLRP3 inflammasome 96 , regulation of autophagy by Atg16L1, autophagy-mediated destruction of inflammasomes 97 , and then the signaling and bioavailability of IL-1β itself. Additional regulation of IL-1β is discussed in the text.
npg r e v i e w such as Il12b, Il6 and Nos2, encode molecules with critical roles in regulating inflammatory and adaptive immunity. Bcl-6 seems to be a similarly potent suppressor of a subset of genes encoding inflammatory molecules, as many LPS-induced genes have been found to be activated much more in macrophages from Bcl-6-deficient mice 61 . Bcl-6 directly binds to control regions of many of the affected genes, which suggests that it may suppress the transcription of these genes by directly competing with transcriptional activators, which might lead a repressive chromatin environment. One possibility that has not yet been explored is that Bcl-6 may recruit Mi-2-NuRD to target genes to limit inducible transcription. Careful comparison of the sets of genes suppressed by the two factors may provide insight into this possibility, as regulation of a common set of genes would suggest that the two factors act in concert. Careful delineation of the genes suppressed by these proteins, preferably by RNA sequencing, may also provide clues to the biological reason for the existence of these suppression mechanisms. Several other transcription factors, including IRF4 and ATF3, have also been linked to the repression of inducible gene transcription 48, 62, 63 . Although it has been possible to document the importance of these repression mechanisms in the context of mutant mice, the manner in which they are integrated into a normal inflammatory response is unknown, and it is not known whether they directly participate in pathways that promote disease.
As discussed above, several factors and mechanisms able to suppress or limit the transcription of genes encoding inflammatory molecules have been described, but their contributions to normal and abnormal inflammatory responses remain to be elucidated. With this in mind, we find it interesting to consider an independent line of investigation that originated with a biological observation that is probably of considerable importance, but for which the underlying mechanisms have remained incompletely understood for many years. Specifically, it has long been known that exposure to a potent inflammatory stimulus can lead to acquired resistance to the induction of genes encoding inflammatory molecules after subsequent stimulation. This observation was first made with LPS as the stimulus and is referred to as 'LPS tolerance' or 'endotoxin tolerance' . However, TNF has similarly been shown to induce tolerance 43 .
Many molecular mechanisms seem to contribute to tolerance, ranging from mechanisms for suppressing the transduction of an inflammatory signal to active repression of genes encoding inflammatory molecules through the assembly of repressive chromatin structures [64] [65] [66] . The existence of so many mechanisms has made it difficult to determine the relative importance of each mechanism that has been described. A few notable studies have provided compelling evidence that changes in chromatin structure contribute to the stable suppression of inducible transcription 43, 65, 67, 68 . Repressive histone modifications and chromatin changes that may prevent remodeling by ATP-dependent nucleosome-remodeling complexes have been suggested to contribute to resistance to transcriptional activation. Interestingly, only a subset of inducible genes has been found to be susceptible to LPS tolerance, with tolerance observed for some genes encoding molecules that contribute to inflammation but not for genes encoding molecules that contribute to antimicrobial immunity 44 .
An attractive hypothesis is that the two groups of genes may have distinguishing chromatin characteristics that confer resistance or sensitivity to tolerance. However, initial efforts to identify such distinguishing characteristics have been unsuccessful, as both sensitive and resistant genes were included in a group of genes found to be dependent on nucleosome remodeling for their activation 44, 60, 69 . Genes that are sensitive and resistant to tolerance induction have also been found in a class of nucleosome remodeling-independent genes. The two classes of genes also cannot be distinguished on the basis of common histone modifications in unstimulated and stimulated cells. Therefore, much remains to be learned about LPS tolerance and the precise mechanisms by which chromatin structure and other events, including signal transduction, contribute to this process.
IL-10 signaling integrates many regulatory strata Genetics has taught that IL-10 is the central anti-inflammatory cytokine that affects many anti-inflammatory strata. The effects of germline deletion of the genes encoding IL-10 or its receptor (IL-10R) produce extremely deleterious and often lethal inflammatory syndromes in both humans and mice 9, 70 . In mice housed in normal or specific pathogen-free conditions, the effects of IL-10 disruption are first observed in the gut, as noted above. In contrast, germ-free IL-10-deficient mice do not have colitis 71 , which indicates that the intestinal flora drives the excessive inflammatory response. Furthermore, mice that lack MyD88 and IL-10 do not have colitis, which provides conclusive evidence that excessive signaling TLRs and the IL-1 receptor (IL-1R) in the intestine must be continuously suppressed by 73) . Indeed, depending on the stimulus or infection, pathogenic inflammatory responses are observed in most models of acute and chronic inflammation in IL-10-deficient mice 74 . However, the anti-inflammatory effects of IL-10 come at a cost, because IL-10 also inhibits productive inflammatory responses to intracellular pathogens, especially Mycobacteria and Leishmania 75, 76 . Thus, the IL-10 anti-inflammatory signal is a trade-off between deleterious and productive inflammatory responses. Another evolutionary curiosity of IL-10 concerns its nonredundant nature in mammals. If IL-10 is so important, why are there not many IL-10-like cytokines? Although the answers to this question are speculative, one possibility is that only one IL-10-IL-10R system is required and if it does not function properly, then early death from excessive inflammation is likely, which removes the causative mutation from the gene pool (similarly, some other essential cytokines such as erythropoietin and G-CSF may have the same properties).
IL-10 signaling is dependent on the transcription factor STAT3 (refs. 47,77; Fig. 2 ). The use of STAT3 raises the problem of deciphering how IL-10 suppresses TLR-induced transcription, because STAT3 is activated by many cytokines 78, 79 . In IL-10-responsive myeloid cells, IL-6 is also a potent activator of STAT3, yet IL-6 mediates none of the suppressive effects of IL-10. The underlying mechanism involved in this dichotomy is mediated by inhibition of the IL-10 'signal' from the IL-6 receptor by SOCS3, whereas IL-10R does not bind SOCS3 (ref. 80) . Furthermore, any cytokine receptor can be engineered into an 'IL-10R' by ensuring activation of STAT3 in the absence of SOCS3 inhibition 81 . Thus, the IL-10-mediated anti-inflammatory response is 'generic' in that it depends on a specific way of activating STAT3 independently of the receptor. The underlying mechanisms involved in the 'IL-10 type' of activation of STAT3 relative to that of other STAT3-activating receptors remain unknown.
The effects of IL-10 (like LPS tolerance and inhibition of steroid hormones) on transcription are gene specific: many TLR-regulated genes (such as Nfkbia and Tnfaip3) are unaffected by IL-10, whereas others show varying degrees of inhibition, from complete (Il12b) to partial (Tnf) 47 . The underlying mechanisms involved in the selection of genes for inhibition remain unknown 82, 83 . Two mechanisms are possible: a single 'master regulatory factor' could mediate transcriptional repression, or many factors could work together (Fig. 3) . In the former case, no unique IL-10-regulated factor has been identified that would be epistatic to STAT3 (refs. 47,84,85). Instead, it seems likely npg r e v i e w that many factors suppress gene expression in a gene-specific way. So far, the best understood of these is NFIL3, a basic leucine zipper factor induced by IL-10 that regulates Il12b (which encodes IL-12p40, the common subunit of IL-12 and IL-23) by binding to a distal enhancer ~10 kilobases upstream of the Il12b promoter [86] [87] [88] . NFIL3-deficient macrophages overproduce IL-12p40 and the subunit IL-12p70 in response to stimulation via TLRs 88, 89 . However, although NFIL3 is necessary for the regulation of Il12b transcription, it is not sufficient, because IL-10 retains residual inhibitory effects on Il12b transcription in Nfil3 −/− macrophages 88, 89 . Therefore, additional factors induced by IL-10 that are associated with transcription, including Bcl-3, Sbno2, Etv3 and IkBNS, may work together to suppress TLR-induced genes, along with factors that possibly regulate elongation on actively transcribed TLR-regulated genes 83, 88 .
Although most of the inhibitory effects of IL-10 are focused on transcriptional control, IL-10 also induces additional modifiers of inflammatory signaling that operate on other strata. For example, IL-10, via STAT3, increases the TLR-mediated expression of TTP to enhance the degradation of target mRNAs with AU-rich 3′ untranslated regions targeted for degradation by TTP 90 . In the same time frame, IL-10 synergistically induces DUSP1, which can dephosphorylate the mitogenactivated kinase p38 (ref. 91) . As p38-mediated phosphorylation of TTP is inactivating, DUSP1 maintains TTP activity, which further enhances the effects of IL-10 on mRNA stability (Fig. 1) . Another target of IL-10 is the gene encoding the IL-1R antagonist IL-1RA, whose expression is induced substantially by IL-10. Therefore, IL-10 regulates IL-1 signaling at the transcriptional, post-transcriptional and receptor levels in concert with other inhibitory processes (Fig. 1) . A final example of the dichotomy of the anti-inflammatory effects of IL-10 is the regulation of LPS-induced microRNA. IL-10 is a potent transcription inhibitor of the proinflammatory microRNA miR-155 but not of miR-146 (ref. 92 ), which has cell-intrinsic anti-inflammatory effects 50 . How the IL-10 signaling pathway makes this discrimination remains unknown.
Decoys, antagonists and 'hijacked' cytokines
The removal of TLR-induced proinflammatory cytokines and chemokines after production, coupled with receptor antagonism, are key 'downstream' anti-inflammatory processes that are often overlooked in deciphering inflammatory control in vivo 93 . The removal of cytokines after production has been harnessed for successful therapy; examples of this include soluble TNF receptors for the treatment of rheumatoid arthritis and inflammatory bowel disease (etanercept), and IL-1RA for the treatment of inflammatory cryopathies (anakinra). Soluble proinflammatory mediators are removed or inhibited by distinct mechanisms. For example, membrane-bound and soluble cytokine and chemokine receptors act as 'sinks' in a variety of different cell types to 'soak up' proinflammatory mediators. The production of IL-10 by myeloid cells has been described 24 (and this figure was inspired by that report 24 ).
npg r e v i e w
Another type of inhibitory mechanism involves the active production of decoy receptors that inhibit a selected group of cytokines, including IL-1, IL-13 and IL-22. Decoy receptors are nonsignaling receptors with an affinity for their ligand equal or greater than that of the signaling receptor. For example, the IL-13Rα2 decoy receptor binds IL-13 and has an essential role in blocking IL-13 and T helper type 2-mediated inflammation 94 .
A final type of inhibition involves the production of cytokine mimics that act as receptor antagonists. The best characterized example of this is the inhibition of IL-1R signaling by IL-1RA, which competes with IL-1α and IL-1β for binding to IL-1R and blocks signaling 95 . Why do so few cytokines have decoy receptors? Although it is conceivable that IL-1, IL-13 and IL-22 have a high potential for inflammatory tissue destruction, other cytokines with known connections to pathogenic inflammation, including IFN-γ, IL-12 and IL-23, lack decoy receptors. Therefore, the decoy receptor system for IL-1, IL-13 and IL-22 probably has a fine-tuning role in inflammation that could be exploited therapeutically for other cytokines.
The 'hijacking' of cytokines by viruses also raises a similar selectivity problem. IL-10 has been shown to be 'hijacked' in at least three cases (by Epstein-Barr virus, cytomegalovirus and Orf poxvirus); and IL-6, once (Kaposi's sarcoma-associated herpes virus). However, most viruses that can fit additional genes into their genomes lack 'virokines' (virus-encoded proteins that act as competitive inhibitors of host cytokines), even though these molecules have powerful effects on host immune modulation. As with the cytokine decoy receptors, opportunities exist for engineering new drugs that can modulate acute and chronic inflammation with low toxicity (because of the selectivity for a given receptor).
Perspectives
In this brief overview, we have attempted to emphasize that the pathways that restrain inflammation operate on many levels and over broad time frames. Constitutive and inducible inflammation is regulated by a multitude of cell-intrinsic and cell-extrinsic mechanisms that are themselves regulated. Given that a large fraction of clinical medicine and health is connected to inflammatory diseases and that many of the most successful drugs target inflammation, it seems likely that new opportunities for disease mitigation can be developed by observing how the body naturally regulates inflammation. To achieve this goal, researchers need better tools and techniques to understand complex signaling pathways. Cell-specific deletions will be also needed to assess molecular function in whole-animal models of acute and chronic inflammation, and these will need to be coupled to more sophisticated and realistic mouse models of inflammation, which will be essential for the translation of such studies to humans. Finally, comparative studies of animal models, human tissue samples and ex vivo primary cell cultures will be essential for pinpointing the key features of inflammatory control relevant to humans.
